Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan Pharma Market Crosses 11 Trillion Yen in FY2023, Keytruda Triumphs: IQVIA
The Japanese pharmaceutical market expanded 3.7% in FY2023, topping 11 trillion yen on an NHI price basis with Keytruda (pembrolizumab) grabbing the No.1 spot, according to data released by IQVIA. At 11,370.8 billion yen, total revenues exceeded the previous year…
To read the full story
Related Article
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
- Japan Patented Drug Market Breaks 7 Trillion Yen in FY2023: IQVIA
August 9, 2024
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…